Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Escherichia HNA1b immuno globulin extra cellular trans membrane HNA1a HNA1c anti body Fc gamma RIIIb CD16 FCRIII FCGR3
- Product Overview:
Low affinity immunoglobulin ? Fc region receptor IIIb (Fc?RIIIb) has roles in neutrophil adhesion, phagocytosis, and the respiratory burst.{59450} It is encoded by the FCGR3B gene in humans and is comprised of two immunoglobulin-like (Ig-like) extracellular domains that bind to IgG Fc and pentraxins, such as C-reactive protein. Fc?RIIIb is synthesized as a precursor with a transmembrane domain and four-residue cytoplasmic domain that are cleaved in the endoplasmic reticulum, following which a glycosylphosphatidylinositol (GPI) anchor is added, which allows for membrane association of the mature protein.{59451,59450} It can be expressed as three different allotypes known as human neutrophil antigens HNA-1a, HNA-1b, and HNA-1c, which are characterized by differential antibody binding affinities.{59450} Fc?RIIIb is constitutively expressed in neutrophils and a subset of basophils and is shed from the cell surface as a soluble form via proteolytic cleavage during apoptosis or following neutrophil activation.{59450,59452} Copy number variation of FCGR3B is associated with an increased risk of systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome.{59453} Cayman’s Fc?RIIIb/CD16b HNA-1b allotype (human, recombinant) protein consists of 176 amino acids and has a calculated molecular weight of 20 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.